期刊文献+

去分化联合IDO基因修饰增强人脐带间充质干细胞的抗氧化应激存活及Treg细胞诱导能力 被引量:1

Enhanced Cell Surviving against Oxidative Stress and Treg-inducing Ability of Dedifferentiated Human Umbilical Cord Mesenchymal Stem Cells Modified by IDO Gene
下载PDF
导出
摘要 【目的】研究去分化处理联合吲哚胺-2,3-双加氧酶(IDO)基因修饰,对人脐带间充质干细胞(hMSC)抗氧化应激生存能力及诱导调节性T淋巴细胞(Treg)能力的影响。【方法】通过对hMSC的短暂成脂分化诱导和恢复培养,获得去分化hMSC(De-hMSC)。实验组De-hMSC感染携带IDO基因的重组逆转录病毒,对照组为感染绿色荧光蛋白(ZsGreen1)基因的De-hMSC以及正常培养的未感染De-hMSC和hMSC。通过Western blot检测被感染细胞的IDO蛋白表达,应用流式细胞术测定IDO基因修饰型De-hMSC(IDO/De-hMSC)的免疫表型,同时鉴定其成骨和成脂分化能力。利用Annexin V-FITC/PI双染流式细胞术比较各组细胞在300μmol/L t-BHP作用下的抗氧化应激生存能力,采用三色荧光标记流式细胞术测定含各组细胞培养上清的条件培养基对正常人外周血单个核细胞(PBMC)中Treg细胞含量的影响。【结果】IDO/De-hMSC仍具有间充质干细胞的免疫表型和成骨、成脂分化能力。在300μmol/L t-BHP作用下,De-hMSC的细胞存活率较hMSC明显增加(P<0.05),经IDO基因修饰后De-hMSC的细胞存活优势无明显改变(P>0.05)。与未修饰的各对照组相比,含IDO/De-hMSC上清的条件培养基能明显上调PBMC中CD4^+CD25^+CD127^(low)Treg细胞的含量(P<0.05)。【结论】成脂去分化联合IDO基因修饰不影响hMSC的干细胞特性,并能同时增强h MSC的抗氧化应激生存能力及其对Treg细胞的诱导能力,是一种有望在免疫抑制治疗中发挥作用的间充质干细胞修饰策略。 【Objective】To investigate whether the dedifferented human umbilical cord mesenchymal stem cells(hMSC)modified by IDO gene can get improved ability to survive oxidative stress as well as to induce regulatory T(Treg)lymphocytes.【Methods】The dedifferentiated h MSC(De-hMSC)were obtained by a transient adipogenic induction and subsequent recovery culture in normal medium.The IDO gene modified De-hMSC(IDO/De-hMSC)were prepared by retroviral infection using recombinant retrovirus harboring IDO gene.The De-hMSC infected by retrovirus containing ZsGreen1 gene,the non-infected De-hMSC and h MSC were set as controls.Exogenous expression of IDO protein wasconfirmed by Western blot.Flow cytometry analysis was performed to detect the immunophenotype of IDO/De-hMSC,and their osteogenic/adipogenic differentiation abilities were also assessed.Cell survival rates under the oxidative stress of300μmol/L t-BHP were determined by Annexin V-FITC/PI double staining flow cytometry.Human peripheral blood mononuclear cells(PBMC)were isolated and treated with conditioned medium containing the culture supernatant of hMSC,De-hMSC,Mock/De-hMSC and IDO/De-hMSC,respectively.Changes in the proportion of CD4+CD25+CD127low Treg cells in PBMC were determined by triple fluorescent labeling flow cytometry.【Results】The De-hMSC modified by IDO gene still have the immunophenotype as well as the osteogenic/adipogenic differentiation abilities that are typical of mesenchymal stem cells.When challenged by 300μmol/L t-BHP,the number of viable cells in De-hMSC significantly elevated compared with hMSC(P<0.05),and the survival advantage of De-hMSC was not obviously affected by IDO gene modification(P>0.05).Conditioned medium containing the supernatant from IDO/De-hMSC dramatically up-regulated the percentage of CD4+CD25+CD127lowTreg cells in PBMC in contrast to the control groups(P<0.05).【Conclusions】IDO/De-hMSC have the same immunophenotype and differentiation capacity as the native hMSC,and can simultaneously enhance the ability of hMSC to survive against oxidative stress and to induce Treg cells,which may be a potential modification strategy of mesenchymal stem cells for immunosuppressive therapy.
作者 匡梅娜 黄思瑞 鲁欣 周畅 胡耀华 唐震林 袁茵 KUANG Mei-na;HUANG Si-rui;LU Xin;ZHOU Chang;HU Yao-hua;TANG Zhen-lin;YUAN Yin(School of Biosciences and Biopharmaceutics,Guangdong Pharmaceutical University,Guangzhou 510006,China;College of Life Science,South China Normal University,Guangzhou 510631,China)
出处 《中山大学学报(医学版)》 CAS CSCD 北大核心 2019年第2期187-194,共8页 Journal of Sun Yat-Sen University:Medical Sciences
基金 国家自然科学基金(81502973) 广东省自然科学基金(2014A030310259) 广东药科大学"创新强校工程"资助项目(2014KQNCX142)
关键词 人脐带间充质干细胞 去分化 吲哚胺-2 3-双加氧酶 基因修饰 human umbilical cord mesenchymal stem cells dedifferention indoleamine-2,3-dioxygenase gene modification
  • 相关文献

参考文献6

二级参考文献28

  • 1孙星,裘国强,徐军明,彭志海.大鼠肝移植后的排斥反应与吲哚胺2,3双加氧酶基因的关系[J].中华器官移植杂志,2006,27(7):392-395. 被引量:4
  • 2王国霞,曹福亮,陈军.Progress in Researches on the Pharmaceutical Mechanism and Clinical Application of Ginkgo Biloba Extract on Various Kinds of Diseases[J].Chinese Journal of Integrative Medicine,2006,12(3):234-239. 被引量:22
  • 3Gioia R, Panaroni C, Besio R, et al. Impaired osteoblasto-genesis in a routine model of dominant osteogenesis imperfecta:a new target for osteogenesis imperfecta pharmacological therapy [ J ]. Stem Cell, 2012,30 (7) : 1465-1476.
  • 4Barry FP,Murphy JM. Mesenchymal stem cells:clinical applications and biological characterization [J]. Int J Biochem Cell Biol, 2004,36(4) : 568-584.
  • 5Zhao LR, Duan WM, Reyes M, et al. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats[J]. Exp Neurol, 2002,174( 1 ) : 11-20.
  • 6Chanda D, Kumar S,Ponnazhagan S. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton [J]. J Cell Biochem, 2010,111 (2) :249-257.
  • 7Tumbar T, Guasch G, Greco V, et al. Defining the epithe- lial stem cellniche in skin [J]. Science,2004,303 (5): 359-363.
  • 8Blanpain C, Lowry WE, Geoghegan A, et al. Self-renewal,multipotency and the existence of two cell populations within an epithelial stem cell niche [J]. Cell,2004,118 (5) : 635-648.
  • 9Liu Y,Jiang X,Zhang X,et al. Dedifferentiation-repro- grammed mesenchymal stem cells with improved thera- peutic potential [J]. Stem Cells,2011,29 (12):2077- 2089.
  • 10Hallman MA,Zhuang S,Schnellmann RG. Regulation of dedifferentiation and redifferentiaition in renal proximal tubular cells by the epidermal growth factor Receptor[J]. J Pharmacol Exp Ther, 2008,325 (2) : 520-528.

共引文献31

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部